Septerna (NASDAQ:SEPN) Stock Price Up 9.2% - Should You Buy?

Key Points

• Septerna, Inc. saw a significant share price increase of 9.2%, trading at $15.71, despite a 79% decline in average trading volume.
• Analysts have given the stock a mixed reception, with four analysts rating it as a Buy and others setting a consensus price target of $26.75.
• In its latest earnings report, Septerna reported a substantial earnings miss with ($0.56) earnings per share, far below the consensus estimate of ($0.05).

Septerna, Inc. (NASDAQ:SEPN - Get Free Report)'s stock price traded up 9.2% on Thursday . The company traded as high as $15.72 and last traded at $15.71. 130,738 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 630,129 shares. The stock had previously closed at $14.39.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. HC Wainwright reissued a "buy" rating and issued a $26.00 target price on shares of Septerna in a report on Thursday, August 21st. Wall Street Zen raised Septerna from a "sell" rating to a "hold" rating in a report on Sunday. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of Septerna in a report on Friday, September 5th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Septerna currently has an average rating of "Moderate Buy" and an average target price of $26.75.

Septerna Price Performance

The firm has a 50 day moving average price of $12.82 and a 200 day moving average price of $9.77.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.51). The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $22.50 million. Septerna had a negative return on equity of 31.52% and a negative net margin of 12,053.03%. On average, research analysts expect that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Septerna

Institutional investors have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new position in Septerna during the 1st quarter valued at approximately $49,000. BNP Paribas Financial Markets purchased a new position in Septerna during the 4th quarter valued at approximately $52,000. Chicago Partners Investment Group LLC purchased a new position in Septerna during the 1st quarter valued at approximately $63,000. Deutsche Bank AG grew its holdings in Septerna by 53.3% during the 1st quarter. Deutsche Bank AG now owns 15,968 shares of the company's stock valued at $92,000 after buying an additional 5,549 shares in the last quarter. Finally, Stoneridge Investment Partners LLC purchased a new position in Septerna during the 1st quarter valued at approximately $107,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.